<DOC>
	<DOCNO>NCT01819272</DOCNO>
	<brief_summary>This study compare effect delayed-release metformin ( Met DR ) placebo extend release metformin ( Met XR ) glycemic control ( fast plasma glucose HbA1c ) body weight , assess safety tolerability range dose Met DR administer subject type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Assessing Efficacy , Safety , Tolerability Met DR Subjects With T2DM Over 12 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Male female T2DM ≥18 ≤65 year age Visit 1 2 . Had body mass index ( BMI ) 25.0 kg/m² 45.0 kg/m² , inclusive , Visit 1 3 . Screening HbA1c 7.0 9.5 % ( inclusive ) Visit 1 treated diet exercise alone , 6.0 9.5 % ( inclusive ) stable dose either metformin DPP4 inhibitor monotherapy minimum 2 month Visit 1 , combination 2 agent stable regimen minimum 2 month Visit 1 4 . Had serum creatinine concentration &lt; 1.5 mg/dL ( male ) &lt; 1.4 mg/dL ( female ) estimate glomerular filtration rate ( eGFR ) ≥60 mL/min/1.73 m² base Modification Diet Renal Disease ( MDRD ) equation 5 . Had fast glucose concentration &lt; 280 mg/dL Visit 1 6 . Had stable body weight , i.e. , vary &gt; 5 % least 6 month prior Visit 1 document investigator 7 . Was male , female meet follow criterion : 1 . Not breastfeed 2 . Negative pregnancy test result ( human chorionic gonadotropin , beta subunit [ βhCG ] ) Visit 1 ( applicable hysterectomized female ) 3 . If child bear potential ( include perimenopausal woman menstrual period within 1 year ) , must practice willing continue practice appropriate birth control entire duration study 8 . Had physical examination ECG clinically significant abnormality judge investigator Visit 1 9 . Had clinically significant laboratory test value ( clinical chemistry , hematology , urinalysis ) expect subject diabetes judged investigator Visit 1 10 . Either treat stable treatment regimen follow medication minimum 2 month prior Visit 1 : 1 . Hormone replacement therapy ( female subject ) 2 . Oral contraceptive ( female subject ) 3 . Antihypertensive agent 4 . Lipidlowering agent 5 . Thyroid replacement therapy 6 . Antidepressant agent 7 . Testosterone therapy ( male subject ) 11 . If chronic thyroid pharmacologic therapy , serum thyroidstimulating hormone test result within normal range Visit 1 12 . Was willing able follow study procedures 13 . Was able read , understand , sign Informed Consent Form Authorization Use Disclose Protected Health Information form , answer study question , communicate investigator , understand comply protocol requirement 1 . Had clinically significant medical condition could potentially affect study participation and/or personal wellbeing , judge investigator , include limited following condition : 1 . Hepatic disease 2 . Renal disease 3 . Gastrointestinal disease 4 . Endocrine disorder except T2DM 5 . Cardiovascular disease 6 . Central nervous system diseases 7 . Psychiatric neurological disorder 8 . Organ transplantation 9 . Chronic acute infection ( e.g. , tuberculosis , human immunodeficiency virus , hepatitis B virus , hepatitis C virus ) 10 . Orthostatic hypotension , faint spell blackouts 11 . Allergy hypersensitivity 2 . Clinically significant malignant disease ( exception basal squamous cell carcinoma skin ) within 5 year Visit 1 3 . Had know hypersensitivity , intolerability , allergy metformin HCl component study treatment 4 . Had physical , psychological , historical finding , investigator 's opinion , would make subject unsuitable study 5 . Current drug alcohol abuse history abuse investigator 's opinion would cause individual noncompliant study procedures 6 . Had major surgery blood transfusion within 2 month Visit 1 planning donate blood study , significant blood loss within 2 month prior Visit 1 7 . Had treat , treat , expect require undergo treatment follow excluded medication : 1 . Insulin sulphonylurea treatment within 3 month Visit 1 2 . GLP1 receptor agonist and/or thiazolidinedione treatment within 6 month Visit 1 3 . Nifedipine within 3 month Visit 1 4 . Systemic corticosteroid oral , intravenous , intraarticular , intramuscular route within 30 day screen 1 week within 3 month Visit 1 5 . Prescription weight loss medication within 3 month Visit 1 6 . Chronic frequent use , judgment investigator , drug treatment affect gastric pH ( prescription overthecounter ) , include proton pump inhibitor antacids medication Rolaids Pepcid within 1 month Visit 1 7 . Had receive plan receive iodinate contrast dye within 1 week prior Visit 1 ( Screening ) 8 . Had surgical gastrointestinal procedure may impact gut hormonal response study medication 9 . History presence inflammatory bowel disease severe gastrointestinal disease , particularly may impact gastric emptying , gastroparesis , pyloric stenosis , gastric bypass surgery gastric band surgery 10 . Had receive investigational drug within 30 day ( five halflives investigational drug , whichever great ) Visit 1 11 . Was immediate family member ( spouse , parent , child , sibling ; biological legally adopt ) personnel directly affiliate study clinical study site , directly affiliate study clinical study site 12 . Was employ Elcelyx Therapeutics , Inc. ( employee , temporary contract worker , designee responsible conduct study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>